Evidence map›Paper›PMID 39546614›Full record

ReviewRevista medica del Instituto Mexicano del Seguro Social2024

[POEMS syndrome. Report of three cases and literature review].

Crhistian Alejandro Aguilar-Vázquez, Nallely Denisse Ruvalcaba-Sánchez

Abstract readCase ReportsReviewEnglish Abstract
In one paragraph

Review in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Crhistian Alejandro Aguilar-VázquezInstituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda", Servicio de Neurofisiología. Ciudad de México, México.ORCID 0000-0001-6400-2564a
Nallely Denisse Ruvalcaba-SánchezInstituto Mexicano del Seguro Social, Hospital General de Zona No. 30, Servicio de Neurología. Ciudad de México, México.ORCID 0000-0002-5441-2647b

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: POEMS syndrome is a debilitating paraneoplastic disorder associated with plasma cell neoplasia. Clinically, it is characterized by predominantly demyelinating peripheral neuropathy that often starts in the pelvic limbs, organomegaly, endocrinopathy, skin changes, and elevated serum M protein. Diagnosis requires meeting a set of clinical criteria in which polyradiculoneuropathy and plasma cell disorder are the two mandatory criteria. The aim of this article is to describe 3 clinical cases, their diagnostic approach, and therapeutic management. Clinical Cases: In this study, three clinical cases with features compatible with POEMS syndrome are presented. Nerve conduction studies revealed demyelinating involvement with sensory-motor impairment, and evidence of a monoclonal spike was found. Treatment was successful in two cases and partially effective in one, although the latter was associated with delayed diagnosis. Conclusion: Despite significant advancements in understanding the pathophysiology and treatment of this disease, diagnosis remains challenging, especially in locations lacking the necessary resources for accurate diagnosis. It is essential to emphasize that it requires a multidisciplinary approach. The prognosis of this disease is closely linked to early diagnosis. Here, we describe three cases from a reference center in Mexico to increase awareness of the disease's diagnosis.

Indexed as

POEMS SyndromeHumansParaproteinemiasPOEMS SyndromePolyneuropathies

Identifiers

PMID39546614
PMCPMC12367279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.